

Inaccurate Labelling of Melatonin Gummies: A Concerning Trend

Arun HS Kumar

Stemcology, School of Veterinary Medicine, University College Dublin, Belfield, Dublin, Ireland.

INTRODUCTION

Melatonin gummies have gained popularity as a sleep aid and are widely available over-the-counter.^{1,2} However, a recent analysis of 25 melatonin gummy products has revealed a concerning trend of inaccurate labelling, raising important questions about product quality, consumer safety, and regulatory oversight.³ This editorial aims to highlight the findings of the analysis and discuss the implications for both manufacturers and consumers.

Findings and Implications

The analysis of 25 melatonin gummy products revealed several significant issues:

Inaccurate Melatonin Quantities

The discovery of inaccurate melatonin quantities in the analysed melatonin gummy products is a matter of significant concern. The wide range of discrepancies, spanning from 74% to 347% of the labelled quantity, raises doubts about the reliability and consistency of melatonin dosing in these products. Accurate dosing is crucial when it comes to melatonin, as it is commonly used as a sleep aid and its effectiveness is highly dependent on the correct dosage. Individuals relying on melatonin gummies to regulate their sleep patterns expect consistent and predictable results. However, the significant variation in melatonin content observed in this analysis suggests that consumers may be receiving inconsistent dosages, potentially compromising the efficacy and safety of the product. Moreover, the inaccuracies in melatonin quantities have broader implications for consumer trust in both the specific products and the industry as a whole. Consumers rely on accurate labelling to make informed decisions about their health and well-being. When products fail to meet their labelled claims, it erodes confidence and undermines the trust that consumers place in the industry's commitment to transparency and safety. The consequences of inaccurate dosing can be twofold. On one hand, if the actual melatonin content is lower than stated, individuals may not receive the desired sleep-regulating effects,

leading to frustration and a loss of trust in the product. On the other hand, if the actual melatonin content is higher than labelled, individuals may inadvertently consume excessive doses, potentially resulting in adverse effects or interactions with other medications they might be taking. Ensuring accurate melatonin dosing in products is essential for the well-being of consumers. It is imperative that manufacturers take responsibility for consistent and precise labelling, as well as implementing robust quality control measures to guarantee the reliability of their products. Regular testing by independent laboratories can help identify any discrepancies and ensure compliance with labelling regulations. Regulatory agencies also play a crucial role in addressing these issues. They should strengthen monitoring and enforcement efforts to ensure compliance with labelling guidelines and impose appropriate penalties on non-compliant manufacturers. Random sampling and testing of melatonin gummy products can act as a deterrent, holding manufacturers accountable and protecting consumer interests.

Limited Compliance

The lack of compliance with labelling regulations observed in the analysis of melatonin gummy products is indeed alarming. Out of the 25 products analysed, a mere 12% contained melatonin quantities within $\pm 10\%$ of the declared amount. This indicates a significant failure to meet regulatory standards and highlights the need for stricter quality control measures within the industry. Accurate product labelling is not only a legal requirement but also a critical aspect of consumer safety and confidence. When individuals purchase melatonin gummies, they rely on the information provided on the label to guide their usage and ensure they are receiving the intended benefits. However, the findings of this analysis indicate that the majority of products on the market fail to accurately disclose the amount of melatonin contained in each serving. The implications of such limited compliance are significant. Consumers may unknowingly receive lower or higher doses of melatonin than intended, leading to unpredictable outcomes. For individuals who rely on melatonin to regulate their sleep patterns, this lack of accuracy can have direct consequences on their ability to achieve restful sleep. Moreover, inaccurate labelling prevents consumers from making informed decisions about their health, as they are unable to gauge the appropriate dosage and understand the potential effects of the product. To ensure consumer safety and build trust, manufacturers must



DOI: 10.5530/bems.9.2.10

Copyright Information :

Copyright Author (s) 2023 Distributed under
Creative Commons CC-BY 4.0

Publishing Partner : EManuscript Tech. [www.emanuscript.in]

prioritize accurate product labelling. This requires implementing stringent quality control measures throughout the production process. Regular testing of finished products by independent laboratories can help identify any discrepancies between the labelled and actual quantities of melatonin, ensuring compliance with regulatory standards. Manufacturers should also establish robust internal procedures to monitor and verify the accuracy of labelling information before products reach the market. Stricter quality control measures are not only necessary for consumer safety but also for the overall reputation of the industry. When a significant number of products fail to comply with labelling regulations, it casts doubt on the integrity of the industry as a whole. It erodes consumer trust and raises concerns about the reliability and effectiveness of melatonin gummies as a sleep aid.

Presence of Other Ingredients

The Discovery of Cannabidiol (CBD) in one of the melatonin gummy products raises significant concerns about the potential adulteration of these products with unlisted substances. This finding highlights the importance of accurate ingredient disclosure, as it is critical for individuals with allergies or sensitivities to make informed choices and avoid potential adverse reactions. When individuals consume melatonin gummies, they expect a product that contains only the advertised ingredients. The presence of CBD, which was not listed as an ingredient on the product label, suggests either intentional adulteration or a manufacturing error. In either case, it raises questions about the integrity of the production process and the reliability of the manufacturer. Accurate disclosure of ingredients is not only a matter of transparency but also a vital aspect of consumer safety. Individuals may have allergies or sensitivities to specific substances, and they rely on accurate labelling to avoid potential adverse reactions. Failing to disclose the presence of ingredients like CBD can put vulnerable individuals at risk, as they may unknowingly consume a substance to which they have a known allergy or sensitivity. Furthermore, the absence of detectable serotonin in any of the analysed products indicates compliance with regulatory guidelines regarding the absence of this neurotransmitter. Serotonin is a naturally occurring compound in the body and plays a crucial role in regulating various physiological functions. However, its presence in dietary supplements, including melatonin gummies, is not permitted due to potential safety concerns. The non-detection of serotonin in any of the products, suggests that manufacturers are adhering to regulatory guidelines. This compliance is essential to ensure consumer safety and to prevent any potential interactions or adverse effects associated with the presence of serotonin.

Regulatory Oversight

The findings of the analysis regarding inaccurate melatonin quantities and the presence of unlisted substances in melatonin

gummy products underscore the pressing need for enhanced regulatory oversight and stricter quality control measures within the industry. It is crucial to prioritize consumer health and safety by ensuring accurate product labelling, conducting regular testing, and imposing more significant penalties for non-compliance. Firstly, stricter adherence to labelling guidelines is essential. Manufacturers must be held accountable for accurately disclosing the quantity of melatonin and other ingredients in their products. Clear and precise labelling allows consumers to make informed decisions, especially regarding allergens or substances they wish to avoid. Regulatory agencies should strengthen monitoring and enforcement efforts to ensure manufacturers comply with labelling regulations. This can be achieved through random sampling and testing of products, as well as regular audits of manufacturing facilities to verify compliance. Secondly, regular product testing is crucial to identify any discrepancies between labelled and actual quantities of melatonin and to detect the presence of unlisted substances. Independent laboratories should conduct thorough and standardized testing of melatonin gummies to ensure compliance with regulations. Regular testing can act as a deterrent, encouraging manufacturers to prioritize accurate dosing and ingredient disclosure. Finally, increased penalties for non-compliance are necessary to incentivize manufacturers to adhere to regulations. The consequences for inaccurate labelling and the presence of unlisted substances should be significant enough to deter such practices. Regulatory agencies should have the authority to impose substantial fines, recall products from the market, and even suspend or revoke licenses for repeated non-compliance. These penalties will send a strong message to manufacturers that consumer health and safety are paramount and will foster a culture of accountability within the industry. By implementing these measures, regulatory agencies can protect consumer health, ensure the integrity of the melatonin gummy market, and restore confidence in the industry. Stricter adherence to labelling guidelines, regular product testing, and increased penalties for non-compliance will create an environment where consumers can trust that the products they purchase are accurately labelled, safe, and effective. It is crucial for all stakeholders, including manufacturers, regulatory bodies, and consumers, to work together to establish and maintain high standards within the melatonin gummy industry.

Recommendations and Future Directions

To address the issues identified in this analysis and promote consumer safety, several actions should be considered: 1) Improved Quality Control: Manufacturers should implement robust quality control measures to ensure accurate and consistent dosing of melatonin. Regular testing of products by independent laboratories can help identify any discrepancies between labelled and actual quantities. 2) Enhanced Regulatory Oversight: Regulatory agencies should strengthen monitoring and enforcement to ensure compliance with labelling regulations.

Random sampling and testing of melatonin gummies can help identify non-compliant products and hold manufacturers accountable. 3) Transparent and Clear Labelling: Manufacturers should provide clear and transparent labelling, accurately listing all ingredients and their quantities. Any potential allergens or additives should be clearly disclosed to enable consumers to make informed choices and 4) Consumer Education: Public awareness campaigns and educational initiatives should be conducted to inform consumers about the potential discrepancies in melatonin gummies and the importance of reading labels critically. This will empower consumers to make informed decisions and demand transparency from manufacturers.

In summary, the analysis of melatonin gummy products reveals a troubling trend of inaccurate labelling, highlighting the need for improved quality control, enhanced regulatory oversight, and transparent communication within the industry. Addressing these issues is crucial to protect consumer health, rebuild trust,

and ensure that individuals seeking melatonin as a sleep aid can rely on accurate and effective products.

CONFLICT OF INTEREST

The author declares that there is no conflict of interest.

REFERENCES

1. Lelak, K., Vohra, V., Neuman, M. I., Toce, M. S. and, Sethuraman, U.. Pediatric Melatonin ingestions—United States, 2012–2021. *MMWR Morbidity and Mortality Weekly Report*, 2022, ;71(22), :725-9. doi: <https://doi.org/10.15585/mmwr.mm7122a110.15585/mmwr.mm7122a1>, PMID <https://www.ncbi.nlm.nih.gov/pubmed/3565328435653284>.
2. Skrzelowski, M., Brookhaus, A., Shea, L. A. and, Berlau, D. J.. Melatonin use in pediatrics: evaluating the discrepancy in evidence based on country and regulations regarding production. *The Journal of Pediatric Pharmacology and Therapeutics*, 2021, ;26(1):4-20. doi: <https://doi.org/10.5863/1551-6776-26.1.410.5863/1551-6776-26.1.4>, PMID <https://www.ncbi.nlm.nih.gov/pubmed/3342449533424495>.
3. Cohen, P. A., Avula, B., Wang, Y.-H.H, Katragunta, K. and, Khan, I.. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. *JAMA*, 2023;329(16), :1401-02. doi: <https://doi.org/10.1001/jama.2023.229610.1001/jama.2023.2296>, PMID <https://www.ncbi.nlm.nih.gov/pubmed/3709736237097362>.

Correspondence:

Arun HS Kumar, DVM, PhD,
Room 216, School of Veterinary Medicine,
University College Dublin, Belfield,
Dublin-04, Ireland.
Email: arun.kumar@ucd.ie
Fax: 00353017166104

Received: 30-04-2023;

Revised: 04-05-2023;

Accepted: 06-05-2023.

Cite this article: Kumar AHS. Inaccurate Labelling of Melatonin Gummies: A Concerning Trend. *BEMS Reports*. 2023;9(2):45-7.